Soleno Therapeutics Inc (SLNO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -119,868 | -43,252 | -21,398 | -38,988 | -27,692 |
| Depreciation Amortization | 1,484 | 984 | 490 | 1,958 | 1,469 |
| Accounts payable and accrued liabilities | 3,094 | 567 | 4,865 | 1,372 | 1,338 |
| Other Working Capital | 3,409 | -2,105 | 1,939 | 2,928 | 1,023 |
| Other Operating Activity | 66,776 | 13,627 | 1,576 | 7,790 | 5,236 |
| Operating Cash Flow | $-45,105 | $-30,179 | $-12,528 | $-24,940 | $-18,626 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -210 | -19 | -11 | N/A | N/A |
| Purchase Of Investment | -308,915 | -261,146 | -115,233 | N/A | N/A |
| Sale Of Investment | 77,000 | 25,000 | N/A | N/A | N/A |
| Investing Cash Flow | $-232,125 | $-236,165 | $-115,244 | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 155,962 | 153,687 | 938 | 180,019 | 56,461 |
| Financing Cash Flow | $155,962 | $153,687 | $938 | $180,019 | $56,461 |
| Beginning Cash Position | 169,681 | 169,681 | 169,681 | 14,602 | 14,602 |
| End Cash Position | 48,413 | 57,024 | 42,847 | 169,681 | 52,437 |
| Net Cash Flow | $-121,268 | $-112,657 | $-126,834 | $155,079 | $37,835 |
| Free Cash Flow | |||||
| Operating Cash Flow | -45,105 | -30,179 | -12,528 | -24,940 | -18,626 |
| Capital Expenditure | -210 | -19 | -11 | N/A | N/A |
| Free Cash Flow | -45,315 | -30,198 | -12,539 | -24,940 | -18,626 |